MAP2K7 and Miyoshi myopathy: Examples include the development of the CDK4/6 inhibitor Palbociclib for MM with CCND1 and CDKN2C mutations [13], the development of the RAF kinase inhibitor Encorafenib (LGX818; RAF kinase inhibitor) and the MEK inhibitor Binimetinib (MEK162) for MM with BRAF V600E/K mutation [2,13,14].